2.306USD-7.85%Mkt Cap: —P/E: —2d ago
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR m…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value89.62M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.01M $
Revenue/Share—
Last Price2.306 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.67
EV/Revenue—
P/S—
P/B2.61
EPS (TTM)-2.25
EPS (Forward)—
52W Range
2.3060% of range2.502
52W High2.502 USD
52W Low2.306 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.98%
ROA-33.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.97M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-56.58M $
Net Debt/EBITDA2.95
Balance Sheet
Debt/Equity1.04
Current Ratio23.40
Quick Ratio23.07
Book Value/Sh0.8830 USD
Cash/Share0.9020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float35.69M
Insiders16.00%
Institutions65.76%
Technical
SMA 501.435 (+60.7%)
SMA 2001.121 (+105.7%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)3.82K
Avg Vol (10d)1.02K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—